The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
June 26th 2025
Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients with hemophilia A or B.
Study Finds Low Natural Antibody Response to Clostridioides difficile
March 27th 2022The presence of antigen-specific and neutralizing antibodies was not associated with Clostridioides difficile infection symptoms, severity, therapy approach, treatment response, or recurrences in a new exploratory study.
Read More
Ruxolitinib Cream Shows Improved Efficacy, Sustained Safety in Vitiligo After Extended Follow-up
March 26th 2022Late-breaking findings at the 2022 American Academy of Dermatology Annual Meeting showed ruxolitinib cream was associated with clinically significant improvement in facial and total body repigmentation vs vehicle in the treatment of adolescent and adult patients with nonsegmental vitiligo over 52 weeks.
Read More
Delving Into Clinical, Epidemiological Differences of Adult, Pediatric Atopic Dermatitis
March 26th 2022Jonathan Silverberg, MD, PhD, MPH, discusses key differences regarding epidemiology, genetic risk factors, and clinical manifestations of pediatric and adult-onset atopic dermatitis, as well as recommended therapeutic approaches for adult patients.
Read More
Obesity Increases Risk of MM Precursor, While Weight Loss Indicates Risk of Cancer Diagnosis
March 25th 2022Weight and changes in it can indicate implications for cancer risk and cancer diagnosis, according to 2 abstracts being presented at the American Association for Cancer Research Annual Meeting.
Read More
Infliximab Biosimilar Maintains Outcomes, Remission Status After Switch From Originator
March 24th 2022Patients switched from the originator product maintained their clinical outcomes and remissions status while biologic-naïve patients recorded positive responses and remission outcomes after initiating infliximab-dyyb.
Read More
Dr Shoaib Ugradar Discusses Teprotumumab for Thyroid Eye Disease and Data Collected
March 21st 2022Teprotumumab has shown great efficacy in treating thyroid eye disease in both clinical trials and real-world settings, but more data are needed on adverse events, said Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica.
Watch
Examining Adjuvant Therapies in PD When Levodopa Wanes
March 19th 2022A randomized clinical trial examined patient quality of life in Parkinson disease (PD) when adding different adjuvant therapies to levodopa to help control dyskinesia and a flaring of symptoms during OFF periods to see if one drug class had any benefit over another.
Read More
Increasing Rates of Women Receive Testing for Obstructive Sleep Apnea Diagnosis, According to Study
March 19th 2022A recent study found that older men with higher body mass index are more likely to receive a diagnosis of obstructive sleep apnea, but women are accounting for a growing number of new diagnoses.
Read More
Current Strategies and the Potential of CAR T-Cell Therapy in Relapsed and Refractory MCL
March 19th 2022Mantle cell lymphoma is a difficult cancer type with high relapse rates, but novel targeted approaches such as CAR T-cell therapy hold promise for more successful response rates in the future.
Read More
Dupilumab Meaningfully Reduces Symptoms for Patients With EoE, Study Finds
March 19th 2022Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to abstracts presenting findings from the 3-part LIBERTY-EoE-TREET study.
Read More
FDA Approves FoundationOne CDx to Identify EGFR Therapeutics for Certain Patients With NSCLC
March 19th 2022FoundationOne CDx has been approved as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 alternations eligible for treatment with EGFR tyrosine kinase inhibitors.
Read More